Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Targeting BRAF and MEK in Colorectal Cancer

July 31st 2019

BRAF Mutations in Colorectal Cancer

July 31st 2019

Emerging Treatment Strategies for Advanced BRAF+ Melanoma

July 31st 2019

Sequencing Therapy in Metastatic BRAF+ Melanoma

July 31st 2019

Selecting Therapy & Managing Patients With BRAF+ Melanoma

July 31st 2019

Trials and Treatment in Advanced Melanoma

July 31st 2019

Recommendations for Molecular Testing in Melanoma

July 31st 2019

BRAF and MEK in Melanoma

July 31st 2019

Developments in the Management of Stage III Melanoma

July 31st 2019

Unmet Needs in BRAF+ NSCLC

July 31st 2019

Treatment Considerations for BRAF+ NSCLC

July 31st 2019

Molecular Testing in NSCLC

July 31st 2019

Targeting BRAF in NSCLC

July 31st 2019

Novel Surgical Strategies at the Forefront in Lung Cancer

July 30th 2019

Matthew Steliga, MD, discusses key surgical updates in lung cancer and the shifting role of surgery with the emergence of novel therapies.

Dr. Bazhenova on New Developments in RET-Rearranged NSCLC

July 28th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses new developments in RET-rearranged non–small cell lung cancer.

Dr. Wakelee on Advances in EGFR-Mutant NSCLC Treatment

July 28th 2019

Heather A. Wakelee, MD, professor of medicine (oncology), Stanford University Medical Center, discusses osimertinib and its role in treating patients with EGFR-mutant non–small cell lung cancer.

Immunotherapy Combos, Novel Strategies Aim to Address Unmet Needs in Small Cell Lung Cancer

July 27th 2019

With the arrival of immunotherapy to the small cell lung cancer armamentarium, combination approaches with targeted therapies are now in the pipeline to stimulate further clinical activity, such as adding PARP or CHK1 inhibitors.

Wealth of Immunotherapy Combinations Places Emphasis on Biomarkers for NSCLC

July 27th 2019

The magnitude of data becoming available on immunotherapy combinations for patients with non–small cell lung cancer has made treatment selection complicated.

Novel Therapies Elicit Excitement in KRAS+ NSCLC

July 27th 2019

The early potential shown with the KRAS inhibitor AMG 510 coupled with several promising ongoing combination studies has ushered in the beginning of an exciting era for the treatment of KRAS-mutant non–small cell lung cancer.

Osimertinib Frontline Standard of Care for EGFR+ NSCLC

July 27th 2019

The frontline standard of care for patients with EGFR-mutant non–small cell lung cancer remains an EGFR TKI, most commonly osimertinib in the United States.